decrease kidney function and proteinuria is risk factor for heart disease and kidney disease
In a phase 2b study, efruxifermin added to stable GLP-1RA therapy in MASH patients with T2D was safe and reduced hepatic fat fraction by 65% vs. 10% with GLP-1RA alone. It also improved noninvasive fibrosis and metabolic markers without impacting weight loss benefits.
Did you know? Statins are linked to a 9–12% increased risk of new-onset diabetes, particularly with long-term, high-dose use and in patients with impaired glucose regulation. Still, their cardiovascular benefits usually outweigh this risk, prompting continued use in most at-risk populations.
Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?
Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?
Source : https://pubmed.ncbi.nlm.nih.gov/39761874/
Although often overlooked sleep apnea has emerged as a significant public health concern. Obstructive sleep apnea (OSA) and diabetes commonly co-exist with a vicious cycle worsening the incidence and severity...
Obstructive sleep apnea and diabetes synergistically worsen cardiovascular outcomes. This review highlights their interplay, shared risk markers, and the importance of integrated screening, diagnosis, and treatment strategies to mitigate complications.